Stock PER PERCHERON THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Percheron Therapeutics Limited

Equities

PER

AU0000317281

End-of-day quote Australian S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
0.081 AUD +9.46% Intraday chart for Percheron Therapeutics Limited +12.50% +37.29%
May. 29 Percheron Therapeutics Completes Enrollment for Phase Two Muscular Dystrophy Trial; Shares Rise 3% MT
May. 20 Percheron Therapeutics Secures US Patent for Muscular Dystrophy Medicinal Candidate MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets
GL
Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets
GL
Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets
AQ
New Muscle Disease Indication for ATL1102 – Limb Girdle Muscular Dystrophy R2
GL
New Muscle Disease Indication for ATL1102 – Limb Girdle Muscular Dystrophy R2
AQ
Antisense Therapeutics : Prospectus
PU
Antisense Therapeutics to present poster at world’s largest NMD conference
GL
Antisense Therapeutics to present poster at world’s largest NMD conference
GL
Antisense Therapeutics : Application for quotation of securities - ANP
PU
Antisense Therapeutics : Quarterly Report and Appendix 4C
PU
Antisense Therapeutics : Application for quotation of securities - ANP
PU
Antisense Therapeutics : Application for quotation of securities - ANP
PU
Antisense Therapeutics : Annual General Meeting Presentation
PU
Antisense Therapeutics : Update - Proposed issue of securities - ANP
PU
Antisense Therapeutics : Morgans rates ANP as Add
AQ
Antisense Therapeutics : Announces a Poster Presentation on the Muscular Dystrophy Association Virtual Conference 2020 website
BU
Antisense Therapeutics : ATL1102 Final Phase II DMD Results Meet Primary Endpoint and Exceed Expectations on Secondary Endpoints
BU
Antisense Therapeutics : Announces Appointment of US-based Consultant Medical Director
BU
Antisense Therapeutics : Appointment of Non-Executive Director (G Pace)
PU
Antisense Therapeutics : ATL1103: Data Presentation at the Society for Endocrinology BES 2015 Conference
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PER Stock
  4. News Percheron Therapeutics Limited
  5. Press Releases